Publicaciones en las que colabora con ATANASIO PANDIELLA ALONSO (9)

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2019

  1. MEK5 promotes lung adenocarcinoma

    The European respiratory journal

2014

  1. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

    Oncogene, Vol. 33, Núm. 2, pp. 148-156

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2013

  1. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

    Leukemia, Vol. 27, Núm. 2, pp. 430-440

2012

  1. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4

2009

  1. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as potential therapeutic target

    PLoS ONE, Vol. 4, Núm. 5

  2. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

2007

  1. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

    Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663